Jetrea approved for treatment of symptomatic vitreomacular adhesion in Canada
Canada has become the first market outside the United States and Europe to approve Jetrea for the treatment of symptomatic vitreomacular adhesion, according to a news release.
Jetrea (ocriplasmin, ThromboGenics) was approved by Health Canada via priority review within 180 days of the new drug submission. Alcon, which holds non-U.S. marketing rights for the drug, will handle commercialization in Canada, the release said.
“We are looking forward to announcing further approvals of Jetrea in other markets shortly,” Patrik De Haes, CEO of ThromboGenics, said in the release.